Cargando…

Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Qing-Yu, Liu, Hai-Yan, Guo, Ze-Yi, Wu, Yan-Ping, He, Guo-Lin, Cai, Lei, Pan, Ming-Xin, Fu, Shun-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855209/
https://www.ncbi.nlm.nih.gov/pubmed/35187075
http://dx.doi.org/10.3389/fmolb.2021.810251
_version_ 1784653606765461504
author Xie, Qing-Yu
Liu, Hai-Yan
Guo, Ze-Yi
Wu, Yan-Ping
He, Guo-Lin
Cai, Lei
Pan, Ming-Xin
Fu, Shun-Jun
author_facet Xie, Qing-Yu
Liu, Hai-Yan
Guo, Ze-Yi
Wu, Yan-Ping
He, Guo-Lin
Cai, Lei
Pan, Ming-Xin
Fu, Shun-Jun
author_sort Xie, Qing-Yu
collection PubMed
description Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3 weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3 weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1 year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6 months.
format Online
Article
Text
id pubmed-8855209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88552092022-02-19 Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy Xie, Qing-Yu Liu, Hai-Yan Guo, Ze-Yi Wu, Yan-Ping He, Guo-Lin Cai, Lei Pan, Ming-Xin Fu, Shun-Jun Front Mol Biosci Molecular Biosciences Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3 weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3 weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1 year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6 months. Frontiers Media S.A. 2022-02-04 /pmc/articles/PMC8855209/ /pubmed/35187075 http://dx.doi.org/10.3389/fmolb.2021.810251 Text en Copyright © 2022 Xie, Liu, Guo, Wu, He, Cai, Pan and Fu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Xie, Qing-Yu
Liu, Hai-Yan
Guo, Ze-Yi
Wu, Yan-Ping
He, Guo-Lin
Cai, Lei
Pan, Ming-Xin
Fu, Shun-Jun
Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
title Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
title_full Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
title_fullStr Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
title_full_unstemmed Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
title_short Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
title_sort case report: one-year delay in the effect of conversion surgery therapy for advanced hepatocellular carcinoma after systemic therapy
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855209/
https://www.ncbi.nlm.nih.gov/pubmed/35187075
http://dx.doi.org/10.3389/fmolb.2021.810251
work_keys_str_mv AT xieqingyu casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT liuhaiyan casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT guozeyi casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT wuyanping casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT heguolin casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT cailei casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT panmingxin casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy
AT fushunjun casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy